These ex vivo expanded, highly enriched Th-2+CD62L+CD4+iNKT cells may have a tremendous potential as novel cell therapeutics for several autoimmune diseases where quantitative and qualitative defects of iNKT cells are linked to the pathogenesis of the disease (65–67). The gene discussed is CD4; the disease is autoimmune disease.